FDA Suggests Use of Biomarker Qualification Program as Possible Model for Approving Novel Excipients
This article was originally published in The Gold Sheet
To encourage the development of novel excipients, FDA has suggested retooling its existing Biomarker Qualification Program from new drugs to new excipients. Instead of using this model solely to qualify the safety of new drugs, it also can be used to assess the safety of new excipients.
You may also be interested in...
The FDA’s proposal to establish a separate review path for novel excipients draws industry plaudits and requests for fine-tuning.
Proposal could yield a bounty of new options for innovative drug delivery systems.
AstraZeneca emptied its warehouses in January. “We said, OK let us pack everything and get it out in the door,” said Tony Mire-Sluis, head of global quality. The firm is allowing only crucial personnel in plants, or those responsible for running a plant or moving products; all others are working from home.